このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Mendus 将来の成長

Future 基準チェック /56

Mendusは、52.8%と60.1%でそれぞれ年率52.8%で利益と収益が成長すると予測される一方、EPSはgrowで70.7%年率。

主要情報

52.8%

収益成長率

70.7%

EPS成長率

Biotechs 収益成長	40.0%
収益成長率	60.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	23 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OM:IMMU - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-38	-38	-38	1
12/31/2025	264	390	390	390	2
12/31/2024	2	-131	-88	-88	2
3/31/2024	28	-107	-163	-160	N/A
12/31/2023	28	-102	-165	-163	N/A
9/30/2023	1	-104	-189	-187	N/A
6/30/2023	1	-116	-91	-91	N/A
3/31/2023	1	-141	-123	-119	N/A
12/31/2022	3	-139	-122	-109	N/A
9/30/2022	2	-128	-124	-114	N/A
6/30/2022	2	-117	-126	-114	N/A
3/31/2022	2	-119	-123	-114	N/A
12/31/2021	0	-133	-139	-138	N/A
9/30/2021	N/A	-148	-130	-129	N/A
6/30/2021	N/A	-138	-112	-111	N/A
3/31/2021	0	-119	-91	-90	N/A
12/31/2020	N/A	-89	-57	-57	N/A
9/30/2020	16	3	11	13	N/A
6/30/2020	16	-11	-7	-5	N/A
3/31/2020	17	-31	-22	-21	N/A
12/31/2019	17	-48	-58	-58	N/A
9/30/2019	0	-118	-114	-114	N/A
6/30/2019	0	-112	-102	-102	N/A
3/31/2019	N/A	-98	-89	-89	N/A
12/31/2018	N/A	-98	-105	-105	N/A
9/30/2018	N/A	-90	-88	-88	N/A
6/30/2018	N/A	-89	-89	-89	N/A
3/31/2018	N/A	-88	-94	-94	N/A
12/31/2017	N/A	-80	N/A	-46	N/A
9/30/2017	N/A	-86	N/A	-76	N/A
6/30/2017	N/A	-77	N/A	-75	N/A
3/31/2017	N/A	-72	N/A	-68	N/A
12/31/2016	N/A	-61	N/A	-59	N/A
9/30/2016	N/A	-48	N/A	-51	N/A
6/30/2016	N/A	-44	N/A	-40	N/A
3/31/2016	N/A	-37	N/A	-33	N/A
12/31/2015	N/A	-38	N/A	-35	N/A
9/30/2015	N/A	-37	N/A	-37	N/A
6/30/2015	N/A	-36	N/A	-40	N/A
3/31/2015	N/A	-33	N/A	-33	N/A
12/31/2014	N/A	-28	N/A	-24	N/A
9/30/2014	N/A	-21	N/A	-18	N/A
6/30/2014	N/A	-16	N/A	-9	N/A
3/31/2014	N/A	-13	N/A	-11	N/A
12/31/2013	N/A	-10	N/A	-10	N/A
9/30/2013	N/A	-8	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IMMUは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: IMMU今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: IMMU今後 3 年以内に収益を上げることが予想されます。

収益対市場: IMMUの収益 ( 60.1% ) Swedish市場 ( 1.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: IMMUの収益 ( 60.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IMMUの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Mendus 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 172%

Consensus revenue estimates decrease by 63%

Consensus revenue estimates increase by 172%

Forecast breakeven date pushed back to 2025

No longer forecast to breakeven

Price target decreased by 23% to kr5.00

Recent updates

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

Chief Executive Officer recently bought kr120k worth of stock

We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate

Mendus AB (Publ) Announces Clinical Pipeline Update

Consensus revenue estimates increase by 172%

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Consensus revenue estimates decrease by 63%

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates increase by 172%

Mendus AB (publ), Annual General Meeting, May 17, 2024

New major risk - Share price stability

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Mendus (STO:IMMU) Is Making Moderate Use Of Debt

Price target decreased by 23% to kr5.00

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Is Mendus (STO:IMMU) Using Debt Sensibly?

Price target decreased to kr5.30

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Is Mendus (STO:IMMU) Using Debt Sensibly?

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Chief Financial Officer recently bought kr216k worth of stock

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr97k worth of stock

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Is Immunicum (STO:IMMU) Using Too Much Debt?

Chief Executive Officer recently bought kr252k worth of stock

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought kr2.4m worth of stock

Interim Chairman of the Board recently bought kr183k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Executive Officer has left the company

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

New 90-day low: kr6.84

Independent Chairman Michael S. Oredsson has left the company